Market closed
Kronos Bio/$KRON
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kronos Bio
Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.
Ticker
$KRON
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
8
ISIN
US50107A1043
Website
Kronos Bio Metrics
BasicAdvanced
$44M
-
-$1.07
1.76
-
Price and volume
Market cap
$44M
Beta
1.76
52-week high
$1.60
52-week low
$0.67
Average daily volume
659K
Financial strength
Current ratio
12.93
Quick ratio
12.658
Long term debt to equity
25.621
Total debt to equity
30.182
Management effectiveness
Return on assets (TTM)
-21.73%
Return on equity (TTM)
-59.49%
Valuation
Price to revenue (TTM)
4.763
Price to book
0.55
Price to tangible book (TTM)
0.55
Price to free cash flow (TTM)
-0.805
Growth
Revenue change (TTM)
21.15%
Earnings per share change (TTM)
-46.48%
3-year earnings per share growth (CAGR)
-28.51%
What the Analysts think about Kronos Bio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Kronos Bio stock.
Kronos Bio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Kronos Bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Kronos Bio News
AllArticlesVideos
KRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRON
Business Wire·2 weeks ago
Shareholder Alert: The Ademi Firm Investigates Whether Kronos Bio, Inc. is Obtaining a Fair Price for Its Public Shareholders
Business Wire·2 weeks ago
Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Kronos Bio stock?
Kronos Bio (KRON) has a market cap of $44M as of May 16, 2025.
What is the P/E ratio for Kronos Bio stock?
The price to earnings (P/E) ratio for Kronos Bio (KRON) stock is 0 as of May 16, 2025.
Does Kronos Bio stock pay dividends?
No, Kronos Bio (KRON) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next Kronos Bio dividend payment date?
Kronos Bio (KRON) stock does not pay dividends to its shareholders.
What is the beta indicator for Kronos Bio?
Kronos Bio (KRON) has a beta rating of 1.76. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.